|January 28, 2014|
|07:06 EDT||MYGN||Myriad Genetics published details of its myVision program|
Myriad Genetics announced that it has published details of its myVision Myriad Variant Classification Program in the journal Clinical Genetics. myVision is the most advanced variant classification program available to determine whether a patient's genetic variant is benign or deleterious. myVision employs a number of robust scientific methods and is backed by Myriad's 20 years of clinical research and testing in more than one million patients. "Patients who receive a genetic test that identifies a variant of uncertain significance, or VUS, do not know if their mutation is benign or deleterious and associated with hereditary cancer risk. This lack of clarity is emotionally difficult and confusing for patients who are making medical decisions and may translate into substantial downstream healthcare costs," said the company.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
|March 4, 2014|
|07:14 EDT||MYGN||NCCN updates guidelines for hereditary colon cancer testing |
Myriad Genetics is pleased to note that the National Comprehensive Cancer Network, or NCCN, has revised its medical guidelines to expand Lynch syndrome screening. Lynch syndrome is the most common cause of hereditary colon cancer in adults. Myriad believes the new guidelines will dramatically expand the number of patients eligible for hereditary colon cancer testing, especially among at-risk asymptomatic patients for whom screening has historically been limited based upon prior guidelines and a lack of insurance reimbursement. Some of the key aspects of the new guidelines include: A recommendation that all patients who meet a five percent or greater risk threshold for Lynch syndrome are appropriate for testing; a recommendation against sequential testing for the five Lynch syndrome genes in lieu of panel testing; an acknowledgement that patients with cancer can proceed directly to sequencing tests without a complicated tissue screening algorithm.
|March 3, 2014|
|07:19 EDT||MYGN||Myriad Genetics publishes clinical study for Prolaris |
Myriad Genetics announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65% of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test. Prolaris is a 46-gene molecular diagnostic test that has been evaluated in 11 clinical studies with more than 5,000 patients.
|February 25, 2014|
|07:16 EDT||MYGN||Myriad Genetics firing on all cylinders, says Cantor|
After meeting with Myriad's management, Cantor thinks that the company could have significant opportunities from the diversification of its PROLARIS and Crescendo products in the near to medium term. The firm raised its price target on the stock to $42 from $39 and reiterates a Buy rating on the shares.
|February 24, 2014|
|09:37 EDT||MYGN||Myriad Genetics price target increased to $48 from $39 at Stephens|
Stephens said a recent meeting with Myriad Genetics' management makes the firm more bullish on the near-term and long-term prospects for the company. The firm raised its price target on the stock to $48 and reiterates its Overweight rating on the shares.